Literature DB >> 6783303

A review of the United States clinical experience of the fluoropyrimidine, ftorafur (NSC-148958).

M A Friedman, R J Ignoffo.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6783303     DOI: 10.1016/s0305-7372(80)80037-5

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  8 in total

1.  Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 14-day schedule.

Authors:  R Pazdur; Y Lassere; E Diaz-Canton; B Bready; D H Ho
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

2.  Cytotoxicity of three novel fluoropyrimidines in cultured L1210 murine lymphocytic leukemia cells.

Authors:  A M Shipp; M H Holshouser; P W Ferguson
Journal:  Pharm Res       Date:  1990-12       Impact factor: 4.200

3.  Polyethylenimine-cyclodextrin-tegafur conjugate shows anti-cancer activity and a potential for gene delivery.

Authors:  Qi-da Hu; Hui Fan; Wei-jian Lou; Qing-qing Wang; Gu-ping Tang
Journal:  J Zhejiang Univ Sci B       Date:  2011-09       Impact factor: 3.066

Review 4.  The oral fluorinated pyrimidines.

Authors:  J S de Bono; C J Twelves
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

Review 5.  Tegafur/uracil + calcium folinate in colorectal cancer: double modulation of fluorouracil.

Authors:  P M Hoff; Y Lassere; R Pazdur
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 6.  Novel oral chemotherapy agents.

Authors:  M E Royce; P M Hoff; R Pazdur
Journal:  Curr Oncol Rep       Date:  2000-01       Impact factor: 5.075

Review 7.  A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer.

Authors:  A A Adjei
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

8.  Oral tegafur in the treatment of gastrointestinal tract cancers: a phase II study.

Authors:  S Palmeri; V Gebbia; A Russo; M G Armata; N Gebbia; L Rausa
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.